Next Article in Journal
You Are Not Alone: The (In)Visible Homeless and the Role of Social Workers and Related Professionals
Next Article in Special Issue
Immunopathological Assessment of the Oral Mucosa in Dermatitis Herpetiformis
Previous Article in Journal
The Association between the Burden of PM2.5-Related Neonatal Preterm Birth and Socio-Demographic Index from 1990 to 2019: A Global Burden Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report

1
Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia University, New Delhi 110025, India
2
Department of Oral Medicine and Radiology, Institute of Dental Sciences, Siksha ‘O’ Anusandhan University, Bhubaneswar 750017, India
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(16), 10066; https://doi.org/10.3390/ijerph191610066
Submission received: 11 April 2022 / Revised: 13 May 2022 / Accepted: 18 May 2022 / Published: 15 August 2022
(This article belongs to the Special Issue Oral Inflammation and Chronic Autoimmune Diseases)

Abstract

:
Highly antiretroviral therapy (HAART) used in Human Immunodeficiency Virus (HIV) treatment may prolong the life span of people living with HIV/Acquired Immune Deficiency Syndrome (AIDS) but may also induce the onset of autoimmune disorders. However, HIV-associated systemic sclerosis (SSc) is an extremely rare occurrence, and only four case reports and two studies documenting this association have been reported to date. We report a rare case of HIV-associated SSc who was referred to us for pain management in her mandibular teeth. A 44-year-old female patient diagnosed with HIV-associated SSc reported a complaint of pain in the lower posterior teeth region. Physical examination revealed typical features of SSc. The pain in her mandibular teeth was due to food lodgement, and she was advised to use toothpaste with a powered toothbrush and mouth stretching exercises, followed by oral prophylaxis. The patient responded well to therapy. HIV-associated SSc is an extremely rare occurrence, with an obscure pathogenic mechanism of HIV-associated autoimmunity. Oral physicians play a crucial role in disease management and should be incorporated into the multidisciplinary team.

1. Introduction

Human immunodeficiency virus (HIV) was initially described in the year 1981. Since then, breakthrough advancements have taken place in the diagnostic and therapeutic protocols, thereby influencing the disease prognosis and prevalence [1]. Over the years, HIV infection has emerged as a universal public health menace. The 2018 statistics of the Joint United Nations Programme on HIV and AIDS (UNAIDS) reported approximately 37.9 million individuals living with HIV, with a 0.8% global HIV infection rate [2].
Highly active antiretroviral therapy (HAART) has a favourable prognosis for people living with HIV/AIDS (PLWHA) by prolonging the life span. However, it may also induce the onset of other co-morbid states, including autoimmune diseases [3].
HAART may act as a double-edged sword. It may diminish the autoimmune episode by restoring the dysregulated immune function [4]. It may also provoke the exacerbation of a latent autoimmune disorder or may trigger a new autoimmune disease’s onset during the immune restoration inflammatory syndrome (IRIS), simulating a delayed hypersensitivity reaction to a foreign or self-antigen [4].
The occurrence of rheumatologic ailments in HIV infection dates way back to the 1980s, and the array of rheumatic conditions (arthralgia, arthritis, myalgia, and myositis) have evolved significantly in the post-HAART period. However, autoimmune connective tissue diseases (such as Sjögren’s syndrome, systemic lupus erythematosus, dermatomyositis, and systemic sclerosis) have infrequently been documented with HIV [5].
The coexistence of autoimmune and inflammatory diseases despite an apparent loss of immunocompetence caused by HIV infection is quite ambiguous [6]. Hence, such cases need to be reported to delineate the complex pathogenic mechanisms involved in HIV-associated autoimmunity. Whether the autoimmune diseases occurred due to HIV itself, HIV-related dysregulated immune system, or molecular simulation between the HIV and self-antigen needs to be further explored.
Systemic sclerosis (SSc) is a rare entity affecting less than 10 per 100,000 individuals annually in both Europe and North America [7]. Patients often complain of dry mouth due to salivary gland fibrosis. Dry-mouth symptoms may predispose to an increased incidence of candida infections and high caries rates [8,9]. Dysphagia and dysphonia may be seen due to tongue stiffness and limited mobility, along with decreased flexibility of the oral mucosa and soft palate [10]. Tooth erosion and dental caries may be seen in cases of patients with oesophagal dysmotility, probably due to the gastroesophageal reflux effect [11]. Fibrous adhesions in the articulating surfaces of the temporomandibular joint may result in pseudoankylosis [9]. Aberrant mandibular movements and subluxation are the other likely dental features. Advanced vascular fibrosis and delayed wound healing pose a challenge to surgical treatment [12]. Periodontal features include a low gingival bleeding index, increased periodontal pocket depth, higher periodontal attachment loss, and multiple foci of gingival recession [13].
Infrequently, SSc may be associated with idiopathic tooth resorption. Extreme resorption may result in painful trigeminal neuropathy (TN) due to compression of the inferior alveolar nerve [14]. These patients are more vulnerable to developing oropharyngeal and tongue carcinoma; hence, these patients should be subjected to a detailed and periodic oral cancer screening, even in cases with a restricted oral opening (e.g., by using an endoscope) [15].
An extensive literature search carried out on the Google Scholar and PubMed search engines revealed only four case reports of HIV-associated SSc [5,16,17,18]. To the best of our knowledge, ours is the fifth reported case. Hereby, we report a rare case of HIV-associated SSc in a 44-year-old female who reported mild pain in the mandibular posterior teeth region and responded well to the prescribed treatment.

2. Case Report

A 44-year-old female patient was referred to our outpatient department (on 8 April 2021) for the complaint of mild, dull, intermittent pain, localized to the lower posterior teeth region, for the last 10–15 days. Her medical history reveals that she was diagnosed with HIV infection in 2012 (retro-positive from her husband). The patient is currently on a TLE regimen of antiretrovirals (tenofovir + lamivudine + efavirenz). Gradually, she developed tightening of the skin with reduced manual dexterity and was diagnosed with SSc in 2017. (Her laboratory investigations and treatment regimen are summarized in Table 1.)
There was considerable weight loss with fluctuating jaundice since 2016, and her blood sugar values and blood pressure were within the normal range. Physical examination revealed that the patient was thin built and malnourished, calm, cooperative with normal intelligence, and responding to commands. Extraoral examination revealed smooth, tense, shiny, non-pinchable skin with a loss of wrinkles and wide-open eyes (mask-like facies). Lower palpebral conjunctiva elicited a pallor appearance. The skin over the forehead appeared dry and hyperpigmented with interspersed areas of hypopigmented macules (“salt and pepper” appearance). Atrophic nasal alae contributed to a sharp pinched appearance of the nose (mouse facies). Reduced oral aperture (microstomia) with circumoral radiating furrows (rhagades) and thinned lips resulted in a “purse-string/fish mouth” appearance (Figure 1A–C). The skin over the hands was hard, smooth, shiny, non-pinchable, and exhibited a “salt and pepper” appearance. Stiffened phalangeal joints on the fingers with reduced manual dexterity and mild resorption of the terminal phalanges were also observed (Figure 1D,E).
Intraoral examination revealed limited mouth opening (22 mm) and decreased intercommisural distance (26 mm). Buccal and labial mucosa were pale, blanched, with palpable fibrotic bands. The tongue was depapillated, rigid, and with restricted protrusive movements. A positive mouth mirror test was suggestive of xerostomia. Generalized marginal gingival inflammation, a mild recession in lower anterior teeth, and generalized pockets were also seen, which may be the cause of pain due to food lodgement in the mandibular posterior teeth region (Figure 2).
Orthopantomogram (OPG) showed generalized PDL space widening, especially pronounced in the right and left mandibular and left maxillary posterior teeth, with mild interdental bone loss seen. Mild flattening of the left condyle was also noticed (Figure 3).
The clinical, radiographic, and serological parameters were suggestive of HIV-associated diffuse SSc. The patient was educated and motivated for oral hygiene maintenance. Mouth stretching exercises (ice cream sticks/tongue blades), use of a toothpaste with a powered toothbrush, and antiseptic mouthwash were explained to the patient. The patient was reviewed after a month and reported improvement in mouth opening, and was then subjected to oral prophylaxis. GutCade probiotics were also advised as maintenance therapy for the regulation of eubiosis. The patient is currently under follow-up with an increased mouth opening (30 mm) (Figure 4).

3. Discussion

The post-HAART era has witnessed a substantial diminution in the prevalence of rheumatic features with HIV infection. However, the emergence of another class of rheumatic disorders encompassing an array of systemic autoimmune and autoinflammatory disorders has gained immense concern and significance and resulted in a new clinical and therapeutic dilemma [19,20,21,22,23].
HIV-associated SSc is an infrequent occurrence, and only four case reports [5,16,17,18] and two studies [24,25] have delineated the association of HIV infection with SSc (Table 2).
Calabrese et al. (2005) evaluated the association of autoimmune disorders with HIV infection in an array of 32 published cases. Most of the cases exhibited de novo autoimmunity, while about 20% described the exacerbation of preceding disorders. The onset of these autoimmune diseases also exhibited significant variation, ranging from occurring briefly after induction of HAART to 27 months, with a mean of 9 months [20]. Cases reported by Dembele et al. [16] and Sikdar et al. [18] demonstrated the simultaneous occurrence of HIV and SSc. However, our findings were in concurrence with the other case reports, which demonstrated that SSc was diagnosed after some time of evolution of the immunosuppression and/or the treatment of HIV [5,17]. Our patient developed features of SSc after 5 years of antiretroviral therapy, most likely due to immune restoration syndrome.
The precise pathogenesis of HIV-associated autoimmunity is still obscure. However, the role of retroviruses, HIV-evoked immune dysfunction causing an autoimmune state, molecular simulation between the viral protein and self-antigens (molecular mimicry), and autoimmune diseases depicting a type of IRIS are the various proposed etiopathogenic mechanisms. HIV infection and autoimmunity may also exist as separate ailments, and the onset of autoimmune disorders may be seen during HIV-evoked immune deficiency [3].
Few affirmative links have advocated the retroviral role in the etiopathogenesis of autoimmune disorders. However, large cohort studies are needed to establish the precise prevalence of autoimmune diseases with HIV [25]. The demonstration of retroviral conserved pol sequences in the sera of systemic sclerosis and mixed connective tissue disease patients (MCTD) may suggest the possible role of retroviruses in the pathogenesis of autoimmune diseases, thus advocating that these sequences may correspond with the onset of an autoimmune reaction to U1-70 kDa polypeptide [26]. Few studies have also exhibited SSc-like extracellular matrix protein production by normal human skin fibroblasts following retroviral protein expression [27]. Long-standing HIV infection results in a gradual diminution of humoral immunity owing to a consistent reduction in the CD4+ T-cell count. Compensatory stimulation of B-Cell proliferation with the increased production of immunoglobulins (mostly abnormal) occurs, and this dysregulated immune mechanism may increase the likelihood of autoimmune disease development [1]. HIV infection may evoke autoantibody production as there is structural antigen simulation between HIV proteins and self-antigens. This molecular simulation between the viral protein and self-antigens causes the antibodies to cross-react and eventually leads to the onset of autoimmune diseases. HIV infection may also result in T-lymphocytes disparity, typified by decreased CD4+ T cells and a proportionate increase in CD8+ T cells. This HIV-evoked T lymphocyte disparity may also attribute to the onset of autoimmune diseases [25]. Published literature has revealed the sequence congruity between viral proteins and self-antigens [28,29,30] (Table 3).
Recent national recommendations in the USA advocate a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) with an integrase strand transfer inhibitor (INSTI) as initial therapy for ART-naïve individuals [31]. However, lifelong ART therapy is mandatory, with no definitive cure. Once the therapy is discontinued, there is a resurgence of the infection. The literature has reported that a combination of immune activators, therapeutic vaccines, and neutralizing antibodies have provided cures in some nonhuman primates, thus posing a hope for future treatment strategies in humans. In vivo delivery of gene-editing tools to either target the virus, boost immunity, or protect cells from infection may also serve as future HIV treatment strategies [32].
SSc is a multisystemic autoimmune disorder characterized by microvascular and immune abnormalities, resulting in cutaneous and internal organ fibrosis. Thick, hardened skin is the distinctive disease manifestation; hence, it has also been termed a “hidebound disease” [8,33]. The disease is categorized into two major forms—(a) a diffuse form, with extensive skin involvement and rapid advanced internal organ involvement, and (b) a localized form, with limited skin involvement (distal of the elbows, knees, fingers, and face). The extent of disease progression, internal organ involvement, and production of specific antibodies form the differentiation basis of these forms [8].
Environmental factors may also induce the development of autoimmune disorders. Exposure to infections (H. pylori, cytomegalovirus, Ebstein–Barr virus), chemicals (silica, organic solvents, xylene), heavy metals (mercury, palladium), and drugs (bleomycin, antiretrovirals) have been proposed as potential triggers for SSc development [34]. The published literature has revealed that scleroderma-like cutaneous lesions have been observed with the injectable fusion inhibitor antiretroviral drug enfuvirtide [35]. Another antiretroviral integrase inhibitor drug, raltegravir, has also been associated with the flares of an autoimmune episode [5].
However, our patient did not report any exposure to these environmental factors, nor was she on any medication known to produce scleroderma-like lesions.
The skin over the extremities, face, and trunk may exhibit hyperpigmentation, with distinct depigmented regions. A “salt and pepper” appearance, characterized by vitiligo-like depigmentation and perifollicular hyperpigmentation, is a distinguishing skin manifestation. This typical appearance, together with skin sclerosis, is a diagnostic sign of SSc [9]. Terminal phalanges resorption, short and claw-like fingers (due to acro-osteolysis), and fingertip ulcerations are also usually seen [8].
Our patient presented a typical “salt and pepper” appearance, predominantly over the forehead and hands. Thick, adherent skin over the extremities, stiffened phalangeal joints on the fingers, reduced dexterity, and mild resorption of terminal phalanges were also observed.
Orofacial manifestations may be seen in approximately 80% of SSc cases. Excessive perioral and periorbital sclerosis result in generalized thickened, non-pinchable skin with smooth, shiny texture, comprising the pathognomic “expressionless,” “mask-like,” or “Mona Lisa” facies or “wide-eyed” appearance [36]. “Mouse facies” result from atrophied nasal alae, giving a sharp-nosed appearance. Lip and perioral sclerosis result in limited mouth opening (microstomia) and width (microcheilia) and distinctive creases radiating from the mouth, giving a “purse-string-like” appearance. Patients often complain of xerostomia, predisposing them to an increased incidence of candidiasis and high caries rates [8,9]. Periodontal features include a low gingival bleeding index, increased periodontal pocket depth, higher periodontal attachment loss, and multiple foci of gingival recession [9,13].
Our patient reported typical orofacial manifestations of SSc—thick, shiny facial skin, expressionless appearance, atrophied nasal alae, reduced interincisal and intercommissural distance with pale, fibrotic mucosa, and a depapillated tongue. Gingival recession in the lower anterior teeth and deep pockets were also seen.
Periodontal ligament space widening and mandibular erosions are the distinctive radiographic manifestations of SSc [8]. Periodontal ligament space widening is the most frequently occurring radiographic presentation, and SSc should be given a place in the differential diagnosis, where the radiographic features demonstrate widened PDL space with intact lamina dura (particularly in non-mobile posterior teeth with widened PDL space in more than one segment) [36].
Another radiographic manifestation reported in these patients is the presence of bilateral, sharply defined, relatively uniform mandibular erosions at the insertion sites of masticatory muscles (angles, coronoid process, condyles, or digastric region) [36]. The blunting of mandibular angles results in a characteristic “tail of the whale” radiographic appearance [9].
The radiographic findings seen in our patient included a widened PDL space (more pronounced in posterior teeth) with intact lamina dura and a slight flattening of the left condylar head.
The treatment of SSc necessitates an integrative strategy by incorporating systemic and dental management. The treatment is aimed at inhibiting the production and the accumulation of fibrous proteins, inhibiting vasculature dysfunction, and diminishing the inflammation. Medical management is aimed at preventing tissue ischemia (calcium channel blockers), inhibiting inflammatory-immune processes (immunosuppressive drugs—methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine A), and inhibiting excess collagen synthesis (D-penicillamine, colchicine) [14].
Most SSc patients present gastrointestinal tract dysfunction and dysbiosis (altered gut microbiota composition) [37]. Paraprobiotics and postbiotics play a proactive role in the maintenance of eubiosis. Paraprobiotics are a novel ancillary treatment strategy for periodontal disease. Paraprobiotics not only serve as an efficacious regimen for the domiciliary maintenance of oral health but also assess the cellular and inflammatory variables due to their immunomodulatory effects [38]. Recently, a postbiotic-based gel containing lactoferrin and aloe barbadensis leaf juice powder was used as a treatment regimen for periodontitis [39].
Numerous medications used as disease-modifying agents in SSc may exhibit orofacial adverse effects. Calcium-channel blockers, primarily used to treat Raynaud’s phenomenon and other vascular manifestations, may evoke gum hypertrophy [40]. Maintaining meticulous oral hygiene along with drug substitution may result in remission of drug-induced gum hyperplasia [41]. Oral ulceration can also be a side effect of SSc pharmacological treatment, which includes methotrexate, azathioprine, and cyclophosphamide, thus requiring substitution of the drugs [15]. The severity of Sicca syndrome may be enhanced in patients receiving anticholinergic antidepressants for psychiatric ailments [42]. Jaw osteonecrosis may result in patients receiving bisphosphonates along with prolonged steroid therapy, either to prevent osteoporosis or to treat corticosteroid-induced osteoporosis. Thus, a detailed oral examination encompassing optimal periodontal health, removal of unrestorable teeth, and completion of all invasive dental procedures is essential before initiating bisphosphonate therapy. Anti-vitamin K anticoagulants may result in spontaneous or induced gingival bleeding, particularly in patients with poor oral hygiene. Anticoagulant therapy should be initiated cautiously in patients taking antifungal therapies and necessitates repeated INR measurements [40].
The oral features in systemic sclerosis necessitate an interdisciplinary and preventive approach [40]. Patients should be educated and encouraged to maintain meticulous oral hygiene [43]. The significance of oral hygiene may be emphasized by instructing proper brushing techniques, thus preventing caries and periodontal diseases (gingivitis, periodontitis, gingival hyperplasia, etc.). The oral sessions should be short and carried out early in the day. These patients should be reviewed biannually to identify any pathology [40].
The diminished manual dexterity due to sclerodactyly, together with inaccessibility due to microstomia, hampers toothbrush manoeuvering, making oral hygiene maintenance difficult. Adapted tools, such as powered toothbrushes and floss forks, may be of help to overcome this limitation [34]. Perioral exercise programs should be carried out regularly. Combined treatments, including physical therapy, mouth stretching exercises, or massages, may result in an improved oral opening [14]. Patients should be advised to have regular physical therapies (tongue blade/ice cream stick exercises) and occupational remedies. This will not only ameliorate the mouth opening but also aid in minimizing contractures [33,43]. Microstomia may further hinder impression-taking for prosthetic rehabilitation. Additionally, soft liners should be used at the base of the prostheses to minimize pain and discomfort while using prostheses made of rigid materials [40].
Xerostomia and xerostomia-related complications (dysgeusia, candidiasis, and dental caries) may be prevented by the use of fluoridated toothpaste, sugar-free candies, artificial saliva, and sialagogues [33,43]. Mouthwash containing baking soda and systemic fluoridation with fluorine-carrying devices and fluoride varnishes are helpful.
Oral ulcers can be managed by the topical application of anaesthetics and antiseptics (such as lidocaine 2% and chlorhexidine) [40].
Our patient was advised to practice mouth-stretching exercises (ice cream sticks/tongue blades) and use a toothpaste and a powered toothbrush, followed by oral prophylaxis. The pain has subsided, and the mouth opening has also improved.

4. Conclusions

HIV-associated systemic sclerosis is an extremely rare occurrence with an obscure pathogenic mechanism of HIV-associated autoimmunity. Oral physicians play a pivotal role in disease management and should be incorporated into the multidisciplinary team. Periodic follow-up emphasizing the maintenance of meticulous oral hygiene, together with physical therapies, such as using tongue blades/ice cream sticks, are necessary measures to maintain oral health in these patients. Probiotics should be incorporated as maintenance therapy for the regulation of eubiosis.

Author Contributions

S.H.: conceptualization, writing—original draft preparation, review and editing of the manuscript. M.A.: resource for clinical pictures, investigations, reviewing and editing the manuscript. R.P.: reviewing and editing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mubder, M.; Azab, M.; Jayaraj, M.; Cross, C.; Lankarani, D.; Dhindsa, B.; Pan, J.J.; Ohning, G. Autoimmune hepatitis in patients with human immunodeficiency virus infection: A systematic review of the published literature. Medicine 2019, 98, e17094. [Google Scholar] [CrossRef] [PubMed]
  2. Okada, A.; Nozaki, Y.; Rai, S.; Kinoshita, K.; Funauchi, M.; Matsumura, I. Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus. Life 2021, 11, 463. [Google Scholar] [CrossRef] [PubMed]
  3. Iordache, L.; Launay, O.; Bouchaud, O.; Jeantils, V.; Goujard, C.; Boue, F.; Cacoub, P.; Hanslik, T.; Mahr, A.; Lambotte, O.; et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun. Rev. 2014, 13, 850–877. [Google Scholar] [CrossRef]
  4. Christoforidou, A.; Galanopoulos, N. Diffuse connective tissue disorders in HIV-infected patients. Mediterr. J. Rheumatol. 2018, 29, 148–155. [Google Scholar] [CrossRef] [PubMed]
  5. Okong’o, L.O.; Webb, K.; Scott, C. HIV-associated juvenile systemic sclerosis: A case report. Semin. Arthritis. Rheum. 2015, 44, 411–446. [Google Scholar] [CrossRef]
  6. Maganti, R.M.; Reveille, J.D.; Williams, F.M. Therapy Insight: The Changing Spectrum of Rheumatic Disease in HIV Infection. Nat. Clin. Pract. Rheumatol. 2008, 4, 428–438. [Google Scholar] [CrossRef]
  7. Bergamasco, A.; Hartmann, N.; Wallace, L.; Verpillat, P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019, 11, 257–273. [Google Scholar] [CrossRef]
  8. Hasan, S.; Khan, R.; Harron, M.; Khwaja, K.; Tarranum, F.; Husain, A. Systemic sclerosis: Case report and literature review. Int. J. Contemp. Dent. 2011, 2, 46–53. [Google Scholar]
  9. Jagadish, R.; Mehta, D.S.; Jagadish, P. Oral and periodontal manifestations associated with systemic sclerosis: A case series and review. J. Indian Soc. Periodontol. 2012, 16, 271–274. [Google Scholar] [CrossRef]
  10. Mabongo, M.; Buch, B.; Hira, P.; Ngwenya, S. Progressive Systemic Sclerosis—An extensive manifestation of Scleroderma. S. Afr. Dent. J. 2015, 70, 156–158. [Google Scholar]
  11. Panchbhai, A.; Pawar, S.; Barad, A.; Kazi, Z. Review of orofacial considerations of systemic sclerosis or scleroderma with report of analysis of 3 cases. Indian J. Dent. 2016, 7, 134–139. [Google Scholar] [CrossRef] [PubMed]
  12. Bali, V.; Dabra, S.; Behl, A.B.; Bali, R. A rare case of hidebound disease with dental implications. Dent. Res. J. 2013, 10, 556–561. [Google Scholar]
  13. Jackowski, J.; Strietzel, F.P.; Hunzelmann, N.; Parwani, P.; Jackowski, A.; Benz, K. Dental implants in patients suffering from systemic sclerosis: A retrospective analysis of clinical outcomes in a case series with 24 patients. Int. J. Implant. Dent. 2021, 7, 118. [Google Scholar] [CrossRef] [PubMed]
  14. Puzio, A.; Przywara-Chowaniec, B.; Postek-Stefańska, L.; Mrówka-Kata, K.; Trzaska, k. Systemic sclerosis and its oral health implications. Adv. Clin. Exp. Med. 2019, 28, 547–554. [Google Scholar] [CrossRef]
  15. Benz, K.; Baulig, C.; Knippschil, S.; Strietzel, F.P.; Hunzelmann, N.; Jackowski, J. Prevalence of Oral and Maxillofacial Disorders in Patients with Systemic Scleroderma—A Systematic Review. Int. J. Environ. Res. Public Health 2021, 18, 5238. [Google Scholar] [CrossRef]
  16. Dembélé, I.A.; Nyanke, N.R.; Traore, D.; Souckho, A.K.; Sy, D.; Cissoko, M.; Sanogo, A.; Sangaré, B.B.; Cisse, O.A.; Dao, K.; et al. Scleroderma and HIV Infection: A Case Report with Literature Review. Open. J. Intern. Med. 2018, 8, 255–260. [Google Scholar] [CrossRef]
  17. Mosquera, J.A.; Ojea, R.; Navarro, C. HIV Infection Associated with Scleroderma: Report of Two New Cases. J. Clin. Pathol. 2010, 63, 852–853. [Google Scholar] [CrossRef]
  18. Sikdar, S.; Grover, C.; Kubba, S.; Yadav, A.; Sahni, V.; Aggarwal, G.; Singh, N.P.; Agarwal, S.K. An Uncommon Cause of Scleroderma. Scand. J. Rheumatol. 2005, 34, 242–245. [Google Scholar] [CrossRef]
  19. Nguyen, B.Y.; Reveille, J.D. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr. Opin. Rheumatol. 2009, 21, 404–410. [Google Scholar] [CrossRef]
  20. Calabrese, L.l.; Kirchner, E.; Shrestha, R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: Emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin. Arthritis. Rheum. 2005, 35, 166–174. [Google Scholar] [CrossRef]
  21. Chen, M.; Yen, Y.F.; Lan, Y.C.; Jen, I.A.; Chuang, P.H.; Lee, C.Y.; Lee, Y.; Lin, Y.-A.; Chen, Y.M.A. Risk of diffuse infiltrative lymphocytosis syndrome in HIV-infected patients: A nationwide population-based cohort study. J. Acquir. Immune Defic. Syndr. 2018, 79, 158–163. [Google Scholar] [CrossRef] [PubMed]
  22. Parperis, K.; Abdulqader, Y.; Myers, R.; Bhattarai, B.; Al-Ani, M. Rheumatic diseases in HIV-infected patients in the postantiretroviral therapy era: A tertiary care center experience. Clin. Rheumatol. 2019, 38, 71–76. [Google Scholar] [CrossRef] [PubMed]
  23. Yang, J.J.; Tsai, M.S.; Sun, H.Y.; Hsieh, S.M.; Chen, M.Y.; Sheng, W.H.; Chang, S.-C. Autoimmune diseases-related arthritis in HIV infected patients in the era of highly active antiretroviral therapy. J. Microbiol. Immunol. Infect. 2015, 48, 130–136. [Google Scholar] [CrossRef] [PubMed]
  24. Yao, Q.; Frank, M.; Glynn, M.; Altman, R.D. Rheumatic Manifestations in HIV-1 Infected In-Patients and Literature Review. Clin. Exp. Rheumatol. 2008, 26, 799–806. [Google Scholar] [PubMed]
  25. Yen, Y.F.; Chuang, P.H.; Jen, I.A.; Chen, M.; Lan, Y.C.; Liu, Y.L.; Lee, Y.; Chen, Y.; Chen, Y.M. Incidence of Autoimmune Diseases in a Nationwide HIV/AIDS Patient Cohort in Taiwan, 2000–2012. Ann. Rheum. Dis. 2016, 76, 1–5. [Google Scholar] [CrossRef]
  26. Prokop, J.; Jagodzinski, P. Identification of retroviral conserved pol sequences in serum of mixed connective tissue disease and systemic sclerosis patients. Biomed. Pharmacother. 2004, 58, 61–64. [Google Scholar] [CrossRef]
  27. Jimenez, S.A.; Diaz, A.; Khalili, K. Retroviruses and the pathogenesis of systemic sclerosis. Int. Rev. Immunol. 1995, 12, 159–175. [Google Scholar] [CrossRef]
  28. Douvas, A.; Takehana, Y.; Ehresmann, G.; Chernyovskiy, T.; Daar, E.S. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. AIDS Res. Hum. Retrovir. 1996, 12, 1509–1517. [Google Scholar] [CrossRef]
  29. Query, C.C.; Keene, J.D. A human autoimmune protein associated with U1 RNA contains a regional homology that is cross-reactive with retroviral p30gag antigen. Cell 1987, 51, 211–220. [Google Scholar] [CrossRef]
  30. Maul, G.G.; Jimenez, S.A.; Riggs, E.; Ziemnicka-Kotula, D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: Sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc. Natl. Acad. Sci. USA 1989, 86, 8492–8496. [Google Scholar] [CrossRef]
  31. Altice, F.; Evuarherhe, O.; Shina, S.; Carter, G.; Beaubrun, A.C. Adherence to HIV treatment regimens: Systematic literature review and meta-analysis. Patient Prefer. Adherence 2019, 13, 475–490. [Google Scholar] [CrossRef] [PubMed]
  32. Deeks, S.G.; Archin, N.; Cannon, P.; Collins, S.; Jones, R.B.; de-Jong, M.A.W.P.; Lambotte, O.; Lamplough, R.; Ndung’u, T.; Sugarman, J.; et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 2021, 27, 2085–2098. [Google Scholar] [CrossRef] [PubMed]
  33. Dixit, S.; Kalkur, C.; Sattur, A.P.; Bornstein, M.M.; Melton, F. Scleroderma and dentistry: Two case reports. J. Med. Case Rep. 2016, 10, 297. [Google Scholar] [CrossRef]
  34. Abbot, S.; Bossingham, D.; Proudman, S.; de-Costa, C.; Ho-Huynh, A. Risk factors for the development of systemic sclerosis: A systematic review of the literature. Rheumatol. Adv. Pract. 2018, 2, rky041. [Google Scholar] [CrossRef] [PubMed]
  35. Wallace, B.J.; Tan, K.B.; Pett, S.L.; Cooper, D.A.; Kossard, S.; Whitfeld, M.J. Enfuvirtide injection site reactions: A clinical and histopathological appraisal. Australas. J. Dermatol. 2011, 52, 19–26. [Google Scholar] [CrossRef] [PubMed]
  36. Anbiaee, N.; Tafakhori, Z. Early diagnosis of progressive systemic sclerosis (scleroderma) from a panoramic view: Report of three cases. Dentomaxillofac. Radiol. 2011, 40, 457–462. [Google Scholar] [CrossRef]
  37. Pellicano, C.; Leodori, G.; Innocenti, G.P.; Gigante, A.; Rosato, E. Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes? Nutrients 2019, 11, 2629. [Google Scholar] [CrossRef]
  38. Butera, A.; Gallo, S.; Pascadopoli, M.; Maiorani, C.; Milone, A.; Alovisi, M.; Scribante, A. Paraprobiotics in Non-Surgical Periodontal Therapy: Clinical and Microbiological Aspects in a 6-Month Follow-Up Domiciliary Protocol for Oral Hygiene. Microorganisms 2022, 10, 337. [Google Scholar] [CrossRef]
  39. Butera, A.; Gallo, S.; Pascadopoli, M.; Taccardi, D.; Scribante, A. Home oral care of periodontal patients using antimicrobial gel with postbiotics, lactoferrin, and aloe barbadensis leaf juice powder vs. conventional chlorhexidine gel: A split-mouth randomized clinical trial. Antibiotics 2022, 11, 118. [Google Scholar] [CrossRef]
  40. Hachulla, E.; Agard, C.; Allanore, Y.; Avouac, J.; Bader-Meunier, B.; Belot, A.; Berezne, A.; Bouthors, A.-S.; Condette-Wojtasik, G.; Constans, J.; et al. French recommendations for the management of systemic sclerosis. Orphanet J. Rare Dis. 2021, 16, 322. [Google Scholar] [CrossRef]
  41. Tajani, A.H.; Nesbitt, S.D. Gingival hyperplasia in a patient with hypertension. J. Clin. Hypertens. 2008, 10, 863–865. [Google Scholar] [CrossRef] [PubMed]
  42. Thombs, B.D.; Taillefer, S.S.; Hudson, M.; Baron, M. Depression in patients with systemic sclerosis: A systematic review of the evidence. Arthritis Rheumatol. 2007, 57, 1089–1097. [Google Scholar] [CrossRef] [PubMed]
  43. Mainassara-Chékaraou, S.; El-Gaouzi, R.; Taleb, B. Oral manifestations of morphea en plaque: Case report. Ann. Med. Surg. 2021, 71, 102891. [Google Scholar] [CrossRef] [PubMed]
Figure 1. (A)—Mask-like facies and salt and pepper appearance of the forehead (B,C)—pinched nose, thin and incompetent lips, and (D,E)—thick skin over hands and stiff joints.
Figure 1. (A)—Mask-like facies and salt and pepper appearance of the forehead (B,C)—pinched nose, thin and incompetent lips, and (D,E)—thick skin over hands and stiff joints.
Ijerph 19 10066 g001
Figure 2. (A)—Reduced mouth opening, (B)—depapillated tongue with restricted protrusion, (C)—mild gingival recession and fibrotic labial mucosa.
Figure 2. (A)—Reduced mouth opening, (B)—depapillated tongue with restricted protrusion, (C)—mild gingival recession and fibrotic labial mucosa.
Ijerph 19 10066 g002
Figure 3. OPG reveals generalized PDL space widening. Mild flattening of the left condyle was also appreciated.
Figure 3. OPG reveals generalized PDL space widening. Mild flattening of the left condyle was also appreciated.
Ijerph 19 10066 g003
Figure 4. (A)—Frontal view. (B,C)—profile views showing improved mouth opening (30 mm) post muscle-stretching exercises and use of toothpaste and powered toothbrush.
Figure 4. (A)—Frontal view. (B,C)—profile views showing improved mouth opening (30 mm) post muscle-stretching exercises and use of toothpaste and powered toothbrush.
Ijerph 19 10066 g004
Table 1. Summary of investigations and treatment regimen.
Table 1. Summary of investigations and treatment regimen.
S. No.InvestigationResults
1.HIV Status
HIV SerologyHIV-1 + ve (retro + ve since 2012)
TLE regimen of ART
CD4 cell count440 cells/mm3
HIV viral load2,214,173 copies/mL
2.Complete Blood Count (CBC)
Hemoglobin (Hb)6.8 g/dL
Total leucocyte count (TLC) 4490 cells/μL
Platelets1.3 lakh platelets/μL
Erythrocyte sedimentation rate (ESR)85 mm/hr
Bleeding time (BT)80 s
Clotting time (CT)42 s
International normalized ratio (INR)1.5
3.Liver function test (LFT)
Albumin2.3 g/dL
Globulin1.0 g/dL
Bilirubin2.6 mg/dL
Alanine transaminase (ALT)71 units/L serum
Aspartate aminotransferase (AST)33 units/L serum
Alkaline phosphatase (ALP)672 IU/L
Hepatitis B surface antigen (HBs Ag)−ve
Anti HCV antibody−ve
α-Feto protein (AFP)34 ng/mL
4.Kidney function test (KFT)
Na+/K+141/4.1 mEq/L
Urea21 mg/dL
Creatinine0.4 mg/dL
Urine (R/M)Normal range
5.Immunologic profile
Antinuclear Antibodies (ANA)1:1000 (Intensity 4+)
Extractable Nuclear Antigens (ENA) profile (ELISA)
Anti ds-DNA autoantibody−ve
Ro (SSA) and La (SSB) autoantibody−ve
Anti Smantibodies−ve
Auto-RNP Ab−ve
Anti Scl-70- Ab+ve (32.96 units/mL)
Anti-mitrochondrial Ab (AMA)+ve (suggestive of autoimmune hepatitis)
Anti smooth muscle Ab (ASMA)+ve (suggestive of autoimmune hepatitis)
Anti cyclic citrullinated peptide (Anti-CCP)−ve
Anti cerulopasmin Ab−ve
6.Radiographic investigations
USG AbdomenMild coarse liver echotexture with surface nodularity, mild ascites
Magnetic resonance cholangiopancreatography (MRCP)Gall bladder cholestasis; hepatomegaly with chronic liver disease; splenomegaly with pulmonary hypertension; bilateral single renal cortical cyst; normal common bile duct (CBD); right and left hepatic ducts and intrahepatic bile duct
High-resolution computed tomography (HRCT)Ground glass opacity with peripheral and sub-pleural distribution suggestive of early stage interstitial lung disease
7.Liver BiopsyRevealed liver cirrhosis with activity compatible with autoimmune hepatitis
8.Current Treatment Regimen
Table Methotrexate15 mg weekly
Table Folvite5 mg weekly
Table Omnacortical5 mg OD
Table Hydroquinone (HCQ)200 mg OD HS
Table Calcitin-D500 mg BD
Table Autrin10 mg OD
Table Etoricoxib90 mg OD HS
Table Pantop40 mg OD
Table 2. Reported studies and cases of HIV infection and SSc.
Table 2. Reported studies and cases of HIV infection and SSc.
S. NoAuthor(s) and YearAge/SexHIV StatusSystemic Sclerosis FeaturesOther Associated Ailments
1.Sikdar et al., 2005 [18]
Simultaneous diagnosis of HIV and SSc
45/FCD4+ lymphocyte count increase observed after 6 months HAART.The patient developed symptoms of SSc in the background of immune suppression and responded well to steroids and HAART therapy-
2.Mosquera JA, et al., 2010 [17]44/MHIV +ve, CD4 cell count = 934 cells/mm3, viral load < 40 copies/mLTumification of forearms, thighs, and legs; Raynaud’s phenomena +ve; skin biopsy revealed scleroderma features+ve HCV serology
3.Mosquera JA, et al., 2010 [17]42/MStage II HIV infectionSkin thickening with spasticity in legs; skin biopsy revealed SSc features+ve HCV and HBV serology; type II diabetes mellitus
4.Okongo LO, et al., 2014 [5]9/FPerinatally acquired HIV; on ART therapy; CD4 cell count = 879 cells/mm3; lower than detectable viral loadRaynaud’s phenomena +ve with fingertip ulceration and digital ischemia; thickened extremities and torso skin; B/L sclerodactyly with limited extension and flexion of fingersCompleted TB therapy at 6 months
5.Dembelae IA et al., 2018 [16]
Concomitant diagnosis of HIV and systemic sclerosis.
56/FHIV stage IIISclerodactyly; +ve Raynaud’s phenomena; +ve anti Scl-70 Abs+ve HBV serology
6.Yao Q, et al., 2008 [24]
Retrospective study; out of 888 HIV diagnosed cases, only 1 case of SSc was seen
45/FHIV +ve (acquired from heterosexual partner)Progressive stiffening of face and extremities skin, mask-like faceRenal insufficiency
7.Yen et al., 2016 [25]
Only 4 cases of SSc out of 20,444 HIV cases
3 males and 1 female1 patient on HAART and 3 patients without HAART--
Table 3. A summary of the sequence congruity between viral proteins and human autoantigen epitopes.
Table 3. A summary of the sequence congruity between viral proteins and human autoantigen epitopes.
Author (s) and YearAutoantigenViral Antigen
Douvas et al., 1996 [28]U1 RNP 70 kD; seen in MCTD and SScHIV gp120/41 envelope complex
Query CC et al., 1987 [29]U1 RNP 70 kD; seen in MCTD and SScRetroviral p30 gag protein
Maul GG et al., 1989 [30]DNA Topoisomerase I 110 kD; seen in diffuse SScRetroviral p30 gag protein
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hasan, S.; Aqil, M.; Panigrahi, R. HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report. Int. J. Environ. Res. Public Health 2022, 19, 10066. https://doi.org/10.3390/ijerph191610066

AMA Style

Hasan S, Aqil M, Panigrahi R. HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report. International Journal of Environmental Research and Public Health. 2022; 19(16):10066. https://doi.org/10.3390/ijerph191610066

Chicago/Turabian Style

Hasan, Shamimul, Mohd. Aqil, and Rajat Panigrahi. 2022. "HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report" International Journal of Environmental Research and Public Health 19, no. 16: 10066. https://doi.org/10.3390/ijerph191610066

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop